Answer
Tildrakizumab specifically binds the p19 subunit of IL-23 without binding IL-12, blocking IL-23’s interaction with its receptor and inhibiting release of proinflammatory cytokines and chemokines.
Sources for this answer
- Ilumetri 100 mg solution for injection in pre-filled syringeAlmirall Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 6Document updated
Sources checked